Boston and Medtronic to fight stent verdict and damages
This article was originally published in Clinica
Boston Scientific and Medtronic have each been ordered to pay large damages to Johnson & Johnson after the companies were found to have infringed J&J's stent patents. In separate pieces of litigation, Boston was told to pay $324.4 million, while Medtronic's figure is $271.1 million. The two companies are likely to appeal.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.